Update from ASCO 2022 – Sarcoma
Update from ASCO 2022 – Sarcoma
SARCOMA update by Prof. Jonathan Trent, University of Miami Hospital, USA
SARCOMA update by Prof. Jonathan Trent, University of Miami Hospital, USA
Prof. Jonathan Trent
Prof. Jonathan Trent
Medical Oncology
University of Miami Health System
United States (US)
| 
2 min
|
Jun 2022
I agree that this educational programme:
Hi. This is Dr. John Trent here at ASCO to discuss the results of the rEECur trial.
Patients with refractory and relapsed Ewing sarcoma only have less than 15% five-year survival rate.
Treatment is controversial. In this update of the rEECur trial patients were randomised to either topotecan plus Cytoxan (cyclophosphamide) vs high-dose ifosfamide 15 g/m2 (3g/m2 D1-5).
As it turns out, patients who were randomised to topotecan plus Cytoxan (cyclophosphamide) had a 10.5 month median overall survival and a 45% one year survival rate.
On the other hand, those patients randomised to high-dose ifosfamide 15 g/m2 (3g/m2 D1-5) enjoyed a 15.4 month overall survival and a 55% one year survival rate.
All of these benefits from high-dose ifosfamide were statistically significant.
This data is applicable to the standard of care of therapy and is indeed practice changing today. Thank you.
Prof. Trent discusses the Sarcoma presentation presented at the ASCO 2022 late breaker pleanary session
- Phase 3 assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. McCabe M, et al. Abstract LBA2, ASCO 2022
For news on other ASCO 2022 late-breakers covering rectal cancer, breast cancer and multiple myeloma, visit our summary video here
SARCOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.
Other programmes of interest
60 min
Other programmes developed by Prof. Jonathan Trent
Prof. Jonathan Trent
Medical Oncology
University of Miami Health System
United States (US)
